144 related articles for article (PubMed ID: 36856039)
1. Private Payer-Negotiated Rates for FDA-Approved Head and Neck Cancer Immunotherapy and Chemotherapy Agents.
Talwar A; Kim S; Yu S; Samant S; Tozan Y; Givi B
Otolaryngol Head Neck Surg; 2023 Oct; 169(4):954-961. PubMed ID: 36856039
[TBL] [Abstract][Full Text] [Related]
2. Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance.
Xiao R; Ross JS; Gross CP; Dusetzina SB; McWilliams JM; Sethi RKV; Rathi VK
JAMA Intern Med; 2022 Jun; 182(6):603-611. PubMed ID: 35435948
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
[TBL] [Abstract][Full Text] [Related]
4. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
5. Private Payer-Negotiated Prices for Outpatient Otolaryngologic Surgery.
Wang AA; Xiao R; Sethi RKV; Rathi VK; Scangas GA
Otolaryngol Head Neck Surg; 2022 Aug; 167(2):262-265. PubMed ID: 34582305
[TBL] [Abstract][Full Text] [Related]
6. Variation in the Price of Head and Neck Surgical Oncology Procedures.
Wu MP; Xiao R; Rathi VK; Sethi RKV
Otolaryngol Head Neck Surg; 2023 Mar; 168(3):536-539. PubMed ID: 35671092
[TBL] [Abstract][Full Text] [Related]
7. Variations in Payer-Negotiated Prices for Head and Neck Reconstructive Surgery.
Wu SS; Rathi VK; Byrne PJ; Fritz MA; Shaye DA; Lee LN; Sethi RKV; Lindsay RW; Xiao R
Otolaryngol Head Neck Surg; 2023 Nov; 169(5):1154-1162. PubMed ID: 37337449
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
9. Hospital Price Transparency in the United States: An Examination of Chargemaster, Cash, and Negotiated, Price Variation for 14 Common Procedures.
Linde S; Egede LE
Med Care; 2022 Oct; 60(10):768-774. PubMed ID: 35948351
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
Sun L; Candelieri-Surette D; Anglin-Foote T; Lynch JA; Maxwell KN; D'Avella C; Singh A; Aakhus E; Cohen RB; Brody RM
JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1022-1028. PubMed ID: 36136306
[TBL] [Abstract][Full Text] [Related]
13. Hospital Markup in Head and Neck Cancer Surgery in the US.
Miller JR; Frick KD; Gourin CG
JAMA Otolaryngol Head Neck Surg; 2022 Dec; 148(12):1147-1155. PubMed ID: 36301556
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
Hirschmann A; Lupatsch JE; Schwenkglenks M; Panje CM; Matter-Walstra K; Espeli V; Dedes KJ; Siano M;
Oral Oncol; 2018 Dec; 87():104-110. PubMed ID: 30527224
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Shirasu H; Yokota T; Kawakami T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Mori K; Onitsuka T
Int J Clin Oncol; 2020 Nov; 25(11):1914-1920. PubMed ID: 32648132
[TBL] [Abstract][Full Text] [Related]
16. Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects.
Rajendra A; Noronha V; Joshi A; Patil VM; Menon N; Prabhash K
Expert Rev Anticancer Ther; 2020 Jan; 20(1):17-29. PubMed ID: 31899993
[No Abstract] [Full Text] [Related]
17. Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance.
Robinson JC; Whaley C; Dhruva SS
N Engl J Med; 2024 Jan; 390(4):338-345. PubMed ID: 38265645
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
Przybylski K; Majchrzak E; Weselik L; Golusiński W
Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
[TBL] [Abstract][Full Text] [Related]
19. Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma.
Ramakrishnan K; Liu Z; Baxi S; Chandwani S; Joo S; Chirovsky D
Future Oncol; 2021 Aug; 17(23):3037-3050. PubMed ID: 34044594
[TBL] [Abstract][Full Text] [Related]
20. Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory: a case report.
Mosca M; Filippini DM; Tober N; Rojas FL; Rihawi K; Di Fabio F
Anticancer Drugs; 2022 Aug; 33(7):691-695. PubMed ID: 35324531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
